fashion -WSS

fashion

author：leisure time 2025-09-01 15:17:17 - browse：23

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Cybersecurity threat forces Lurie Children's to take systems offline

WSS

After Optum profits sink, UnitedHealth makes changes

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Novo Nordisk touts Wegovy study, but still struggling with supply

Montana youths win climate lawsuit against state for promoting fossil fuels

Medicare drug price negotiation’s day in court

The lessons of Aduhelm, an Alzheimer's drug that was not to be

knowledge

fashion

knowledge

Alkermes shareholders re

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Moonlake's readout produced a cash windfall. Risks remain

Covid misinformation case heads to Supreme Court

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA drug safety: Singulair case shows systemic surveillance flaws

Bright Health sells Medicare Advantage business to Molina

What we need to know about Arena Bioworks

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What to know about the judge who will handle the Trump case

hotspot

Idaho college killings prosecutors challenge defense's grand jury claims

FDA drug safety: Singulair case shows systemic surveillance flaws

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Vertigo drug brings hope for rare neuron disorder, Niemann

Patients, digital health players weigh in on FTC's data privacy plan

Juul spent big to court Black leaders to promote its e

entertainment

knowledge

knowledge

entertainment